391 reports of this reaction
3.3% of all LUMACAFTOR AND IVACAFTOR reports
#5 most reported adverse reaction
COUGH is the #5 most commonly reported adverse reaction for LUMACAFTOR AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 391 FDA adverse event reports linking LUMACAFTOR AND IVACAFTOR to COUGH. This represents approximately 3.3% of all 12,020 adverse event reports for this drug.
Patients taking LUMACAFTOR AND IVACAFTOR who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COUGH is moderately reported among LUMACAFTOR AND IVACAFTOR users, representing a notable but not dominant share of adverse events.
In addition to cough, the following adverse reactions have been reported for LUMACAFTOR AND IVACAFTOR:
The following drugs have also been linked to cough in FDA adverse event reports:
COUGH has been reported as an adverse event in 391 FDA reports for LUMACAFTOR AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
COUGH accounts for approximately 3.3% of all adverse event reports for LUMACAFTOR AND IVACAFTOR, making it a notable side effect.
If you experience cough while taking LUMACAFTOR AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.